Works matching DE "ERLOTINIB"

Results: 1036

Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants.

Published in:

2024

By:

Greulich, Heidi;
Chen, Tzu-Hsiu;
Feng, Whei;
Jänne, Pasi A.;
Alvarez, James V.;
Zappaterra, Mauro;
Bulmer, Sara E.;
Frank, David A.;
Hahn, William C.;
Sellers, William R.;
Meyerson, Matthew

Publication type:

Correction Notice

A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.

Published in:

Journal of Neuro-Oncology, 2021, v. 153, n. 2, p. 263, doi. 10.1007/s11060-021-03763-1

By:

El-Khouly, Fatma E.;
Veldhuijzen van Zanten, Sophie E. M.;
Jansen, Marc H. A.;
Bakker, Dewi P.;
Sanchez Aliaga, Esther;
Hendrikse, N. Harry;
Vandertop, W. Peter;
van Vuurden, Dannis G.;
Kaspers, Gertjan J. L.

Publication type:

Article

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.

Published in:

Journal of Neuro-Oncology, 2016, v. 129, n. 1, p. 131, doi. 10.1007/s11060-016-2155-4

By:

Jakacki, Regina;
Foley, Margaret;
Horan, Julie;
Wang, Jiuzhou;
Kieran, Mark;
Bowers, Daniel;
Bouffet, Eric;
Zacharoulis, Stergios;
Gill, Stan

Publication type:

Article

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Published in:

Journal of Neuro-Oncology, 2016, v. 126, n. 1, p. 185, doi. 10.1007/s11060-015-1958-z

By:

Raizer, J.;
Giglio, P.;
Hu, J.;
Groves, M.;
Merrell, R.;
Conrad, C.;
Phuphanich, S.;
Puduvalli, V.;
Loghin, M.;
Paleologos, N.;
Yuan, Y.;
Liu, D.;
Rademaker, A.;
Yung, W.;
Vaillant, B.;
Rudnick, J.;
Chamberlain, M.;
Vick, N.;
Grimm, S.;
Tremont-Lukats, I.

Publication type:

Article

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.

Published in:

Journal of Neuro-Oncology, 2015, v. 121, n. 2, p. 331, doi. 10.1007/s11060-014-1636-6

By:

Wen, Qiuting;
Jalilian, Laleh;
Lupo, Janine;
Molinaro, Annette;
Chang, Susan;
Clarke, Jennifer;
Prados, Michael;
Nelson, Sarah

Publication type:

Article

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

Published in:

2014

By:

Gallego, Oscar;
Cuatrecasas, M.;
Benavides, M.;
Segura, P.;
Berrocal, A.;
Erill, N.;
Colomer, A.;
Quintana, M.;
Balaña, C.;
Gil, M.;
Gallardo, A.;
Murata, P.;
Barnadas, A.

Publication type:

Erratum

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

Published in:

Journal of Neuro-Oncology, 2014, v. 116, n. 2, p. 413, doi. 10.1007/s11060-013-1316-y

By:

Gallego, Oscar;
Cuatrecasas, M.;
Benavides, M.;
Segura, P.;
Berrocal, A.;
Erill, N.;
Colomer, A.;
Quintana, M.;
Balaña, C.;
Gil, M.;
Gallardo, A.;
Murata, P.;
Barnadas, A.

Publication type:

Article

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.

Published in:

Pathology & Oncology Research, 2019, v. 25, n. 2, p. 513, doi. 10.1007/s12253-018-0404-x

By:

Inno, Alessandro;
Di Noia, Vincenzo;
Martini, Maurizio;
D'Argento, Ettore;
Di Salvatore, Mariantonietta;
Arena, Vincenzo;
Schinzari, Giovanni;
Orlandi, Armando;
Larocca, Luigi Maria;
Cassano, Alessandra;
Barone, Carlo

Publication type:

Article

Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.

Published in:

Journal of Cancer Research & Clinical Oncology, 2024, v. 150, n. 2, p. 1, doi. 10.1007/s00432-023-05554-9

By:

Zhang, Hao;
Lin, Juntang;
Yahaya, Badrul Hisham

Publication type:

Article

Comprehensive analysis of resistance mechanisms to EGFR–TKIs and establishment and validation of prognostic model.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 15, p. 13773, doi. 10.1007/s00432-023-05129-8

By:

Yang, Zhengzheng;
Li, Haiming;
Dong, Tongjing;
Li, Guangda;
Chen, Dong;
Li, Shujiao;
Wang, Yue;
Pan, Yuancan;
Lu, Taicheng;
Yang, Guowang;
Zhang, Ganlin;
Cheng, Peiyu;
Wang, Xiaomin

Publication type:

Article

Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 9425, doi. 10.1007/s00432-023-04800-4

By:

Fujiki, Hirota;
Sueoka, Eisaburo;
Watanabe, Tatsuro;
Komori, Atsumasa;
Suganuma, Masami

Publication type:

Article

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 8, p. 4243, doi. 10.1007/s00432-022-04287-5

By:

Hyung, Jaewon;
Yoon, Hyunseok;
Choi, Chang-Min;
Yoon, Shinkyo;
Lee, Dae Ho;
Kim, Sang-we;
Kim, Hyeong-ryul;
Kim, Su Ssan;
Song, Si Yeol;
Lee, Jae Cheol

Publication type:

Article

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 2, p. 865, doi. 10.1007/s00432-022-03984-5

By:

Gursoy, Pınar;
Tatli, Ali Murat;
Erdem, Dilek;
Goker, Erdem;
Celik, Emir;
Demirci, Nebi Serkan;
Sakin, Abdullah;
Atci, Muhammed Mustafa;
Bayram, Ertuğrul;
Telli, Tuğba Akın;
Bilgin, Burak;
Bilici, Ahmet;
Akangunduz, Baran;
Balli, Sevinç;
Demirkazik, Ahmet;
Selçukbiricik, Fatih;
Menekse, Serkan;
Cavdar, Eyyüp;
Ozturk, Akın;
Bekmez, Esma Türkmen

Publication type:

Article

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

Published in:

Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 12, p. 3333, doi. 10.1007/s00432-020-03311-w

By:

Landre, Thierry;
Des Guetz, Gaetan;
Chouahnia, Kader;
Duchemann, Boris;
Assié, Jean-Baptiste;
Chouaid, Christos

Publication type:

Article

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Published in:

Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 7, p. 1375, doi. 10.1007/s00432-018-2649-x

By:

Faehling, M.;
Achenbach, J.;
Staib, P.;
Steffen, U.;
Tessen, H. W.;
Gaillard, V. E.;
Brugger, W.

Publication type:

Article

Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.

Published in:

Journal of Cancer Research & Clinical Oncology, 2015, v. 141, n. 8, p. 1481, doi. 10.1007/s00432-015-1935-0

By:

Timmers, Lonneke;
Boons, Christel;
Moes-ten Hove, J.;
Smit, Egbert;
Ven, Peter;
Aerts, Joachim;
Swart, Eleonora;
Boven, Epie;
Hugtenburg, Jacqueline

Publication type:

Article

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2.

Published in:

Molecules, 2022, v. 27, n. 7, p. 2047, doi. 10.3390/molecules27072047

By:

El-Sayed, Wael A.;
Alminderej, Fahad M.;
Mounier, Marwa M.;
Nossier, Eman S.;
Saleh, Sayed M.;
Kassem, Asmaa F.

Publication type:

Article

Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug–Protein and Drug–Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches.

Published in:

Molecules, 2022, v. 27, n. 4, p. 1265, doi. 10.3390/molecules27041265

By:

Wani, Tanveer A.;
Alanazi, Mohammed M.;
Alsaif, Nawaf A.;
Bakheit, Ahmed H.;
Zargar, Seema;
Alsalami, Ommalhasan Mohammed;
Khan, Azmat Ali

Publication type:

Article

Stability and Formulation of Erlotinib in Skin Creams.

Published in:

Molecules, 2022, v. 27, n. 3, p. 1070, doi. 10.3390/molecules27031070

By:

Nguyen, David;
Secrétan, Philippe-Henri;
Cotteret, Camille;
Jacques-Gustave, Emmanuelle;
Greco, Céline;
Bodemer, Christine;
Schlatter, Joel;
Cisternino, Salvatore

Publication type:

Article

Novel Pyridothienopyrimidine Derivatives: Design, Synthesis and Biological Evaluation as Antimicrobial and Anticancer Agents.

Published in:

Molecules, 2022, v. 27, n. 3, p. 803, doi. 10.3390/molecules27030803

By:

Mohi El-Deen, Eman M.;
Anwar, Manal M.;
El-Gwaad, Amina A. Abd;
Karam, Eman A.;
El-Ashrey, Mohamed K.;
Kassab, Rafika R.

Publication type:

Article

A New Series of Indeno[1,2- c ]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy.

Published in:

Molecules, 2022, v. 27, n. 2, p. 485, doi. 10.3390/molecules27020485

By:

Özdemir, Ahmet;
Ciftci, Halilibrahim;
Sever, Belgin;
Tateishi, Hiroshi;
Otsuka, Masami;
Fujita, Mikako;
Altıntop, Mehlika Dilek

Publication type:

Article

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR.

Published in:

Molecules, 2021, v. 26, n. 21, p. 6423, doi. 10.3390/molecules26216423

By:

Almalki, Faisal A.;
Shawky, Ahmed M.;
Abdalla, Ashraf N.;
Gouda, Ahmed M.

Publication type:

Article

Biflavonoids from Selaginella doederleinii as Potential Antitumor Agents for Intervention of Non-Small Cell Lung Cancer.

Published in:

Molecules, 2021, v. 26, n. 17, p. 5401, doi. 10.3390/molecules26175401

By:

Kang, Fenghua;
Zhang, Sha;
Chen, Dekun;
Tan, Jianbing;
Kuang, Min;
Zhang, Jinlin;
Zeng, Guangyuan;
Xu, Kangping;
Zou, Zhenxing;
Tan, Guishan

Publication type:

Article

Design, Synthesis, Molecular Modeling and Antitumor Evaluation of Novel Indolyl-Pyrimidine Derivatives with EGFR Inhibitory Activity.

Published in:

Molecules, 2021, v. 26, n. 7, p. 1838, doi. 10.3390/molecules26071838

By:

Ahmed, Naglaa M.;
Youns, Mahmoud M.;
Soltan, Moustafa K.;
Said, Ahmed M.;
Kupka, Teobald

Publication type:

Article

5-Aryl-1-Arylideneamino-1 H -Imidazole-2(3 H)-Thiones: Synthesis and In Vitro Anticancer Evaluation.

Published in:

Molecules, 2021, v. 26, n. 6, p. 1706, doi. 10.3390/molecules26061706

By:

Abu Almaaty, Ali H.;
Toson, Eslam E. M.;
El-Sayed, El-Sherbiny H.;
Tantawy, Mohamed A. M.;
Fayad, Eman;
Abu Ali, Ola A.;
Zaki, Islam;
Csuk, René

Publication type:

Article

Molecular Structure, In Vitro Anticancer Study and Molecular Docking of New Phosphate Derivatives of Betulin.

Published in:

Molecules, 2021, v. 26, n. 3, p. 737, doi. 10.3390/molecules26030737

By:

Chrobak, Elwira;
Jastrzębska, Maria;
Bębenek, Ewa;
Kadela-Tomanek, Monika;
Marciniec, Krzysztof;
Latocha, Małgorzata;
Wrzalik, Roman;
Kusz, Joachim;
Boryczka, Stanisław;
Rimpelová, Silvie

Publication type:

Article

Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4- d ]pyrimidines Kinase Inhibitors.

Published in:

Molecules, 2020, v. 25, n. 22, p. 5354, doi. 10.3390/molecules25225354

By:

Greco, Chiara;
Catania, Rosa;
Balacco, Dario Leonardo;
Taresco, Vincenzo;
Musumeci, Francesca;
Alexander, Cameron;
Huett, Alan;
Schenone, Silvia;
Szöllösi, György;
Frank, Eva

Publication type:

Article

In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.

Published in:

Molecules, 2020, v. 25, n. 21, p. 5190, doi. 10.3390/molecules25215190

By:

Sever, Belgin;
Altıntop, Mehlika Dilek;
Özdemir, Ahmet;
Akalın Çiftçi, Gülşen;
Ellakwa, Doha E.;
Tateishi, Hiroshi;
Radwan, Mohamed O.;
Ibrahim, Mahmoud A. A.;
Otsuka, Masami;
Fujita, Mikako;
Ciftci, Halil I.;
Ali, Taha F. S.;
Cotelle, Philippe

Publication type:

Article

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.

Published in:

Molecules, 2017, v. 22, n. 9, p. 1515, doi. 10.3390/molecules22091515

By:

Tae Hwan Kim;
Soyoung Shin;
Sarah Kim;
Bulitta, Jürgen B.;
Kwon-Yeon Weon;
Sang Hoon Joo;
Eunsook Ma;
Sun Dong Yoo;
Gi-Young Park;
Dong Rak Kwon;
Seok Won Jeong;
Da Young Lee;
Beom Soo Shin

Publication type:

Article

Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.

Published in:

Cellular Physiology & Biochemistry (Karger AG), 2018, v. 49, n. 4, p. 1615, doi. 10.1159/000493497

By:

Qian Xiao;
Fang Zheng;
Qing Tang;
Jing-Jing Wu;
Jianhui Xie;
Hai-Ding Huang;
Xiao-bo Yang;
Swei Sunny Hann

Publication type:

Article

Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.

Published in:

Cellular Physiology & Biochemistry (Karger AG), 2015, v. 35, n. 6, p. 2255, doi. 10.1159/000374030

By:

Nie, Peipei;
Hu, Weicheng;
Zhang, Tao;
Yang, Yiju;
Hou, Benxin;
Zou, Zhengzhi

Publication type:

Article

Validated UV Spectrophotometric Methods for the Determination of Anticancer Drug Erlotinib Hydrochloride in Bulk and Tablet Formulations.

Published in:

Journal of Applied Spectroscopy, 2021, v. 88, n. 4, p. 882, doi. 10.1007/s10812-021-01254-9

By:

Rathod, R. D.;
Rathod, L. D.;
Mundada, A. B.;
Patel, H. M.

Publication type:

Article

LncRNA MALAT-1 modulates EGFR-TKI resistance in lung adenocarcinoma cells by downregulating miR-125.

Published in:

Discover Oncology, 2024, v. 15, n. 1, p. 1, doi. 10.1007/s12672-024-01133-7

By:

Luo, Jie;
Ren, Qiaoya;
Liu, Xiaoxi;
Zheng, Qian;
Yang, Ling;
Meng, Mi;
Ma, Hu;
He, Sisi

Publication type:

Article

Dissolution improvement of binary solid dispersions of erlotinib prepared by one-step electrospray method.

Published in:

Biology Methods & Protocols, 2022, v. 7, n. 1, p. 1, doi. 10.1093/biomethods/bpac001

By:

Jahangiri, Azin;
Khalilzad, Fakhronnesa;
Barghi, Leila

Publication type:

Article

Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC.

Published in:

2019

By:

Shamni, Ofer;
Grievink, Hilbert;
Itamar, Batel;
Mishani, Eyal;
Abourbeh, Galith

Publication type:

journal article

Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer.

Published in:

2019

By:

Abravan, Azadeh;
Eide, Hanne Astrid;
Løndalen, Ayca Muftuler;
Helland, Åslaug;
Malinen, Eirik

Publication type:

journal article

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy.

Published in:

Oncology & Therapy, 2021, v. 9, n. 2, p. 489, doi. 10.1007/s40487-021-00152-6

By:

Wang, Chin-Chou;
Chiu, Li-Chung;
Tung, Pi-Hung;
Kuo, Scott Chih-Hsi;
Chu, Chia-Hsun;
Huang, Allen Chung-Cheng;
Wang, Chih-Liang;
Chen, Chih-Hung;
Yang, Cheng-Ta;
Hsu, Ping-Chih

Publication type:

Article

Chordoma: The Quest for Better Treatment Options.

Published in:

Oncology & Therapy, 2016, v. 4, n. 1, p. 35, doi. 10.1007/s40487-016-0016-0

By:

Heery, Christopher

Publication type:

Article

Updates to the National Cancer Institute's PDQ Information from Recently Published Oncology Research.

Published in:: 2017
Publication type:: journal article

Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells.

Published in:

JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju204

By:

Gao, Wen;
Wang, Michael;
Wang, Li;
Lu, Haibo;
Wu, Shuhong;
Dai, Bingbing;
Ou, Zhishuo;
Zhang, Liang;
Heymach, John V.;
Gold, Kathryn A.;
Minna, John;
Roth, Jack A.;
Hofstetter, Wayne L.;
Swisher, Stephen G.;
Fang, Bingliang

Publication type:

Article

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases.

Published in:

JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 7, p. 1, doi. 10.1093/jnci/dju151

By:

Siow Ming Lee;
Lewanski, Conrad R.;
Counsell, Nicholas;
Ottensmeier, Christian;
Bates, Andrew;
Patel, Nirali;
Wadsworth, Christina;
Yenting Ngai;
Hackshaw, Allan;
Faivre-Finn, Corinne

Publication type:

Article

Liquid chromatography-tandem mass spectrometry method development and validation for the determination of erlotinib in human plasma and its application in pharmacokinetic study.

Published in:

Journal of Analytical Chemistry, 2015, v. 70, n. 12, p. 1488, doi. 10.1134/S1061934815120151

By:

Ramarao, N.;
Vidyadhara, S.;
Basaveswara Rao, M.;
Sasidhar, R.;
Surendra Yadav, R.

Publication type:

Article

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 4, p. 612, doi. 10.1002/psp4.13105

By:

Yin, Anyue;
Veerman, G. D. Marijn;
van Hasselt, Johan G. C.;
Steendam, Christi M. J.;
Dubbink, Hendrikus Jan;
Guchelaar, Henk‐Jan;
Friberg, Lena E.;
Dingemans, Anne‐Marie C.;
Mathijssen, Ron H. J.;
Moes, Dirk Jan A. R.

Publication type:

Article

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2020, v. 9, n. 8, p. 456, doi. 10.1002/psp4.12541

By:

Dong, Zhongqi;
Li, Jia;
Wu, Fang;
Zhao, Ping;
Lee, Sue‐Chih;
Zhang, Lillian;
Seo, Paul;
Zhang, Lei

Publication type:

Article

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 2, p. 136, doi. 10.20892/j.issn.2095-3941.2021.0520

By:

Yuchen Guo;
Yangyang Zhou;
Wenxin Qin

Publication type:

Article

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.

Published in:

Cancer Biology & Medicine, 2020, v. 17, n. 3, p. 753, doi. 10.20892/j.issn.2095-3941.2020.0024

By:

Tingting Qin;
Zhujun Liu;
Jing Wang;
Junling Xia;
Shaochuan Liu;
Yanan Jia;
Hailin Liu;
Kai Li

Publication type:

Article

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.

Published in:

Cancer Biology & Medicine, 2014, v. 11, n. 4, p. 270

By:

Guo-Hao Xia;
Yun Zeng;
Ying Fang;
Shao-Rong Yu;
Li Wang;
Mei-Qi Shi;
Wei-Li Sun;
Xin-En Huang;
Jia Chen;
Ji-Feng Feng

Publication type:

Article

Physicochemical characterization and biological evaluation of amorphous solid dispersions of an anticancerous drug: Erlotinib HCl.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-07692-1

By:

Safna Hussan, K. P.;
Babu, Thekkekara D.;
Thayyil, M. Shahin;
Sreeshma, T. S.;
Archana, A.

Publication type:

Article

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/ low miR-200c signature in vivo.

Published in:

Scientific Reports, 2013, p. 1, doi. 10.1038/srep02459

By:

Cufí, Sílvia;
Bonavia, Rosa;
Vazquez-Martin, Alejandro;
Oliveras-Ferraros, Cristina;
Corominas-Faja, Bruna;
Cuyàs, Elisabet;
Martin-Castillo, Begoña;
Barrajón-Catalán, Enrique;
Visa, Joana;
Segura-Carretero, Antonio;
Joven, Jorge;
Bosch-Barrera, Joaquim;
Micol, Vicente;
Menendez, Javier A.

Publication type:

Article

Antitumor effects of erlotinib in combination with berberine in A431 cells.

Published in:

BMC Pharmacology & Toxicology, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s40360-023-00661-2

By:

Cuan, Xiangdan;
Yang, Xingying;
Zhu, Weiwei;
Zhao, Yue;
Luo, Rui;
Huang, Yanping;
Wang, Xuanjun;
Sheng, Jun

Publication type:

Article